Genetically driven predisposition leads to an unusually genomic unstable renal cell carcinoma.
Journal
Discover. Oncology
ISSN: 2730-6011
Titre abrégé: Discov Oncol
Pays: United States
ID NLM: 101775142
Informations de publication
Date de publication:
21 Mar 2024
21 Mar 2024
Historique:
received:
18
08
2023
accepted:
16
02
2024
medline:
21
3
2024
pubmed:
21
3
2024
entrez:
21
3
2024
Statut:
epublish
Résumé
Renal cell carcinoma originates from the lining of the proximal convoluted renal tubule and represents the most common type of kidney cancer. Risk factors and comorbidities might be associated to renal cell carcinoma, while a small fraction of 2-3% emerges from patients with predisposing cancer syndromes, typically associated to hereditary mutations in VHL, folliculin, fumarate hydratase or MET genes. Here, we report a case of renal cell carcinoma in patient with concurrent germline mutations in BRCA1 and RAD51 genes. This case displays an unusual high mutational burden and chromosomal aberrations compared to the typical profile of renal cell carcinoma. Mutational analysis on whole genome sequencing revealed an enrichment of the MMR2 mutational signature, which is indicative of impaired DNA repair capacity. Overall, the tumor displayed a profile of unusual high genomic instability which suggests a possible origin from germline predisposing mutations in the DNA repair genes BRCA1 and RAD51. While BRCA1 and RAD51 germline mutations are well-characterised in breast and ovarian cancer, their role in renal cell carcinoma is still largely unexplored. The genomic instability detected in this case of renal cell carcinoma, along with the presence of unusual mutations, might offer support to clinicians for the development of patient-tailored therapies.
Identifiants
pubmed: 38512353
doi: 10.1007/s12672-024-00894-5
pii: 10.1007/s12672-024-00894-5
doi:
Types de publication
Journal Article
Langues
eng
Pagination
80Subventions
Organisme : HUB LIFE SCIENCE - Advanced Diagnostic- Italian network of excellence for advanced diagnosis (INNOVA)
ID : PNC-E3-2022-23683266
Organisme : HUB LIFE SCIENCE - Advanced Diagnostic- Italian network of excellence for advanced diagnosis (INNOVA)
ID : PNC-E3-2022-23683266
Organisme : HUB LIFE SCIENCE - Advanced Diagnostic- Italian network of excellence for advanced diagnosis (INNOVA)
ID : PNC-E3-2022-23683266
Organisme : Fondazione AIRC per la Ricerca sul Cancro (AIRC)
ID : IG 2022 ID 27366; 2023-2027
Informations de copyright
© 2024. The Author(s).
Références
Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen S, Horwich A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(5):706–720.
Moch H, Amin MB, Berney DM, Compérat EM, Gill AJ, Hartmann A, Menon S, Raspollini MR, Rubin MA, Srigley JR, Hoon Tan P, Tickoo SK, Tsuzuki T, Turajlic S, Cree I, Netto GJ. The 2022 world health organization classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2022;82(5):458–68.
pubmed: 35853783
doi: 10.1016/j.eururo.2022.06.016
Linehan WM, Ricketts CJ. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol. 2019;16(9):539–52.
pubmed: 31278395
doi: 10.1038/s41585-019-0211-5
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T, KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–27.
pubmed: 30779529
doi: 10.1056/NEJMoa1816714
Scelo G, Larose TL. Epidemiology and Risk Factors for Kidney Cancer. J Clin Oncol. 2018;36(36):JCO2018791905.
pubmed: 30372394
doi: 10.1200/JCO.2018.79.1905
Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15(1):55–64.
pubmed: 25533676
doi: 10.1038/nrc3844
Glykofridis IE, Knol JC, Balk JA, Westland D, Pham TV, Piersma SR, Lougheed SM, Derakhshan S, Veen P, Rooimans MA, van Mil SE, Böttger F, Poddighe PJ, van de Beek I, Drost J, Zwartkruis FJ, de Menezes RX, Meijers-Heijboer HE, Houweling AC, Jimenez CR, Wolthuis RM. Loss of FLCN-FNIP1/2 induces a non-canonical interferon response in human renal tubular epithelial cells. Elife. 2021;10: e61630.
pubmed: 33459596
pmcid: 7899648
doi: 10.7554/eLife.61630
Ooi A. Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research. Semin Cancer Biol. 2020;61:158–66.
pubmed: 31689495
doi: 10.1016/j.semcancer.2019.10.016
Denize T, Just PA, Sibony M, Blons H, Timsit MO, Drossart T, Jakubowicz D, Broudin C, Morini A, Molina T, Vano Y, Auvray-Kuentz M, Richard S, Mejean A, Gimenez Roqueplo AP, Burnichon N, Verkarre V. MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features. Mod Pathol. 2021;34(3):647–59.
pubmed: 32770124
doi: 10.1038/s41379-020-0645-6
Feng H, Wang T, Ye J, Yang Y, Huang X, Lai D, Lv Z, Huang Y, Zhang X. SPI1 is a prognostic biomarker of immune infiltration and immunotherapy efficacy in clear cell renal cell carcinoma. Discov Oncol. 2022;13(1):134.
pubmed: 36477668
pmcid: 9729685
doi: 10.1007/s12672-022-00592-0
Xu W, Liu W, Anwaier A, Tian X, Su J, Shi G, Wei S, Qu Y, Zhang H, Ye D. Deciphering the role of miR-187-3p/LRFN1 axis in modulating progression, aerobic glycolysis and immune microenvironment of clear cell renal cell carcinoma. Discov Oncol. 2022;13(1):59.
pubmed: 35799072
pmcid: 9263027
doi: 10.1007/s12672-022-00523-z
Panatta E, Butera A, Celardo I, Leist M, Melino G, Amelio I. p53 regulates expression of nuclear envelope components in cancer cells. Biol Direct. 2022;17(1):38.
pubmed: 36461070
pmcid: 9716746
doi: 10.1186/s13062-022-00349-3
Butera A, Roy M, Zampieri C, Mammarella E, Panatta E, Melino G, D’Alessandro A, Amelio I. p53-driven lipidome influences non-cell-autonomous lysophospholipids in pancreatic cancer. Biol Direct. 2022;17(1):6.
pubmed: 35255936
pmcid: 8902766
doi: 10.1186/s13062-022-00319-9
Nepravishta R, Sabelli R, Iorio E, Micheli L, Paci M, Melino S. Oxidative species and S-glutathionyl conjugates in the apoptosis induction by allyl thiosulfate. FEBS J. 2012;279(1):154–67.
pubmed: 22035263
doi: 10.1111/j.1742-4658.2011.08407.x
Rozenberg JM, Zvereva S, Dalina A, Blatov I, Zubarev I, Luppov D, Bessmertnyi A, Romanishin A, Alsoulaiman L, Kumeiko V, Kagansky A, Melino G, Ganini C, Barlev NA. The p53 family member p73 in the regulation of cell stress response. Biol Direct. 2021;16(1):23.
pubmed: 34749806
pmcid: 8577020
doi: 10.1186/s13062-021-00307-5
Tan A, Prasad R, Lee C, Jho EH. Past, present, and future perspectives of transcription factor EB (TFEB): mechanisms of regulation and association with disease. Cell Death Differ. 2022;29(8):1433–49.
pubmed: 35739255
pmcid: 9345944
doi: 10.1038/s41418-022-01028-6
Fazi B, Melino S, De Rubeis S, Bagni C, Paci M, Piacentini M, Di Sano F. Acetylation of RTN-1C regulates the induction of ER stress by the inhibition of HDAC activity in neuroectodermal tumors. Oncogene. 2009;28(43):3814–24.
pubmed: 19668229
doi: 10.1038/onc.2009.233
Fang J, Feng C, Chen W, Hou P, Liu Z, Zuo M, Han Y, Xu C, Melino G, Verkhratsky A, Wang Y, Shao C, Shi Y. Redressing the interactions between stem cells and immune system in tissue regeneration. Biol Direct. 2021;16(1):18.
pubmed: 34670590
pmcid: 8527311
doi: 10.1186/s13062-021-00306-6
Mauretti A, Neri A, Kossover O, Seliktar D, Nardo PD, Melino S. Design of a novel composite H2 S-releasing hydrogel for cardiac tissue repair. Macromol Biosci. 2016;16(6):847–58.
pubmed: 26857526
doi: 10.1002/mabi.201500430
Dizman N, Philip EJ, Pal SK. Genomic profiling in renal cell carcinoma. Nat Rev Nephrol. 2020;16(8):435–51.
pubmed: 32561872
doi: 10.1038/s41581-020-0301-x
Attalla K, DiNatale RG, Rappold PM, Fong CJ, Sanchez-Vega F, Silagy AW, Weng S, Coleman J, Lee CH, Carlo MI, Durack JC, Solomon SB, Reuter VE, Russo P, Chan TA, Motzer RJ, Schultz ND, Reznik E, Voss MH, Hakimi AA. Prevalence and landscape of actionable genomic alterations in renal cell carcinoma. Clin Cancer Res. 2021;27(20):5595–606.
pubmed: 34261695
pmcid: 8530915
doi: 10.1158/1078-0432.CCR-20-4058
Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG, Spellman PT, Rathmell WK, Linehan WM, Cancer Genome Atlas Research Network. The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23(1):313–26.
pubmed: 29617669
pmcid: 6075733
doi: 10.1016/j.celrep.2018.03.075
Scimeca M, Bonfiglio R, Urbano N, Cerroni C, Anemona L, Montanaro M, Fazi S, Schillaci O, Mauriello A, Bonanno E. Programmed death ligand 1 expression in prostate cancer cells is associated with deep changes of the tumor inflammatory infiltrate composition. Urol Oncol. 2019;37(5):297.e19-297.e31.
pubmed: 30827759
doi: 10.1016/j.urolonc.2019.02.013
Qin Q, Jun T, Wang B, Patel VG, Mellgard G, Zhong X, Gogerly-Moragoda M, Parikh AB, Leiter A, Gallagher EJ, Alerasool P, Garcia P, Joshi H, Mbbs, Galsky M, Oh WK, Tsao CK. Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis. Discov Oncol. 2022;13(1):73.
pubmed: 35960456
pmcid: 9374856
doi: 10.1007/s12672-022-00538-6
Panatta E, Zampieri C, Melino G, Amelio I. Understanding p53 tumour suppressor network. Biol Direct. 2021;16(1):14.
pubmed: 34362419
pmcid: 8348811
doi: 10.1186/s13062-021-00298-3
Ganini C, Amelio I, Bertolo R, Bove P, Buonomo OC, Candi E, Cipriani C, Di Daniele N, Juhl H, Mauriello A, Marani C, Marshall J, Melino S, Marchetti P, Montanaro M, Natale ME, Novelli F, Palmieri G, Piacentini M, Rendina EA, Roselli M, Sica G, Tesauro M, Rovella V, Tisone G, Shi Y, Wang Y, Melino G. Global mapping of cancers: the Cancer Genome Atlas and beyond. Mol Oncol. 2021;15(11):2823–40.
pubmed: 34245122
pmcid: 8564642
doi: 10.1002/1878-0261.13056
Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, et al. Apoptotic cell death in disease-current understanding of the NCCD 2023. Cell Death Differ. 2023;30(5):1097–154.
pubmed: 37100955
pmcid: 10130819
doi: 10.1038/s41418-023-01153-w
Amelio I, Mancini M, Petrova V, Cairns RA, Vikhreva P, Nicolai S, Marini A, Antonov AA, Le Quesne J, Baena Acevedo JD, Dudek K, Sozzi G, Pastorino U, Knight RA, Mak TW, Melino G. p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. Proc Natl Acad Sci U S A. 2018;115(46):E10869–78.
pubmed: 30381462
pmcid: 6243248
doi: 10.1073/pnas.1808314115
Amelio I, Markert EK, Rufini A, Antonov AV, Sayan BS, Tucci P, Agostini M, Mineo TC, Levine AJ, Melino G. p73 regulates serine biosynthesis in cancer. Oncogene. 2014;33(42):5039–46.
pubmed: 24186203
doi: 10.1038/onc.2013.456
Oberst A, Malatesta M, Aqeilan RI, Rossi M, Salomoni P, Murillas R, Sharma P, Kuehn MR, Oren M, Croce CM, Bernassola F, Melino G. The Nedd4-binding partner 1 (N4BP1) protein is an inhibitor of the E3 ligase Itch. Proc Natl Acad Sci U S A. 2007;104(27):11280–5.
pubmed: 17592138
pmcid: 2040890
doi: 10.1073/pnas.0701773104
Melino G, Memmi EM, Pelicci PG, Bernassola F. Maintaining epithelial stemness with p63. Sci Signal. 2015;8(387):re9.
pubmed: 26221054
doi: 10.1126/scisignal.aaa1033
Li K, Luo H, Huang L, Luo H, Zhu X. Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int. 2020;20:16.
pubmed: 31956294
pmcid: 6958913
doi: 10.1186/s12935-019-1091-8
Meier B, Volkova NV, Hong Y, Schofield P, Campbell PJ, Gerstung M, Gartner A. Mutational signatures of DNA mismatch repair deficiency in C. elegans and human cancers. Genome Res. 2018;28(5):666–75.
pubmed: 29636374
pmcid: 5932607
doi: 10.1101/gr.226845.117
Reh WA, Nairn RS, Lowery MP, Vasquez KM. The homologous recombination protein RAD51D protects the genome from large deletions. Nucleic Acids Res. 2017;45(4):1835–47. https://doi.org/10.1093/nar/gkw1204 .
doi: 10.1093/nar/gkw1204
pubmed: 27924006
Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol. 2010;11(2):138–48. https://doi.org/10.1038/nrm2831 .
doi: 10.1038/nrm2831
pubmed: 20029420
Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, Hayward J, Edlund CK, Conti D, Harrington P, Fraser L, Philpott S, Anderson C, Rosenthal A, Gentry-Maharaj A, Bowtell DD, Alsop K, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Høgdall E, Høgdall CK, Jensen A, Kjaer SK, Lubiński J, Huzarski T, Jakubowska A, Gronwald J, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Odunsi K, Goode EL, Menon U, Jacobs IJ, Gayther SA, Pharoah PD. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol. 2015;33(26):2901–7.
pubmed: 26261251
pmcid: 4554751
doi: 10.1200/JCO.2015.61.2408
Yang X, Song H, Leslie G, Engel C, Hahnen E, Auber B, et al. Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D. J Natl Cancer Inst. 2020;112(12):1242–50.
pubmed: 32107557
pmcid: 7735771
doi: 10.1093/jnci/djaa030
King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643–6.
pubmed: 14576434
doi: 10.1126/science.1088759
Rashid MU, Gull S, Faisal S, Khaliq S, Asghar K, Siddiqui N, Amin A, Hamann U. Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan. Fam Cancer. 2011;10(4):709–12.
pubmed: 21751003
doi: 10.1007/s10689-011-9467-5
Kong W, Yang T, Wen X, Mu Z, Zhao C, Han S, Tian J, Zhang X, Zhou T, Zhang Y, Lou F, Cao S, Wang H, Zhang J. Germline mutation landscape and associated clinical characteristics in chinese patients with renal cell carcinoma. Front Oncol. 2021;11: 737547.
pubmed: 34926252
pmcid: 8675086
doi: 10.3389/fonc.2021.737547
Złowocka-Perłowska E, Tołoczko-Grabarek A, Narod SA, Lubiński J. Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland. Hered Cancer Clin Pract. 2022;20(1):13.
pubmed: 35395863
pmcid: 8994347
doi: 10.1186/s13053-022-00220-6
Smith PS, West H, Whitworth J, Castle B, Sansbury FH, Warren AY, Woodward ER, Tischkowitz M, Maher ER. Pathogenic germline variants in patients with features of hereditary renal cell carcinoma: Evidence for further locus heterogeneity. Genes Chromosomes Cancer. 2021;60(1):5–16.
pubmed: 32830346
doi: 10.1002/gcc.22893
Li S, Silvestri V, Leslie G, Rebbeck TR, Neuhausen SL, Hopper JL, et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J Clin Oncol. 2022;40(14):1529–41.
pubmed: 35077220
pmcid: 9084432
doi: 10.1200/JCO.21.02112
De Paolis E, Paris I, Tilocca B, Roncada P, Foca L, Tiberi G, D’Angelo T, Pavese F, Muratore M, Carbognin L, Garganese G, Masetti R, Di Leone A, Fabi A, Scambia G, Urbani A, Generali D, Minucci A, Santonocito C. Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine. Front Oncol. 2023;12:1053035.
pubmed: 36741700
pmcid: 9891372
doi: 10.3389/fonc.2022.1053035
Yan S, Imam M. Progress and prospects in research and clinical practice of hormone receptor-positive, HER-2-negative breast cancer with BRCA1/2 mutations. Discov Oncol. 2023;14(1):110.
pubmed: 37351713
pmcid: 10290022
doi: 10.1007/s12672-023-00732-0
Reza MS, Hossen MA, Harun-Or-Roshid M, Siddika MA, Kabir MH, Mollah MNH. Metadata analysis to explore hub of the hub-genes highlighting their functions, pathways and regulators for cervical cancer diagnosis and therapies. Discov Oncol. 2022;13(1):79.
pubmed: 35994213
pmcid: 9395557
doi: 10.1007/s12672-022-00546-6
Iyevleva AG, Novik AV, Moiseyenko VM, Imyanitov EN. EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: a case report. Urol Oncol. 2009;27(5):548–50.
pubmed: 18625569
doi: 10.1016/j.urolonc.2008.03.022
Wang D, Chen X, Du Y, Li X, Ying L, Lu Y, Shen B, Gao X, Yi X, Xia X, Sui X, Shu Y. Associations of HER2 mutation with immune-related features and immunotherapy outcomes in solid tumors. Front Immunol. 2022;13: 799988.
pubmed: 35281032
pmcid: 8905508
doi: 10.3389/fimmu.2022.799988
Ross K, Jones RJ. Immune checkpoint inhibitors in renal cell carcinoma. Clin Sci (Lond). 2017;131(21):2627–42.
pubmed: 29079639
doi: 10.1042/CS20160894
Lei Q, Yan X, Zou H, Jiang Y, Lai Y, Ung COL, Hu H. Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis. Discov Oncol. 2022;13(1):95.
pubmed: 36171533
pmcid: 9519826
doi: 10.1007/s12672-022-00559-1
Zhou Y, Song S, Yuan B, Wu Y, Gao Y, Wan G, Li G. A Novel CTLA-4 affinity peptide for cancer immunotherapy by increasing the integrin αvβ3 targeting. Discov Oncol. 2022;13(1):99.
pubmed: 36195696
pmcid: 9532478
doi: 10.1007/s12672-022-00562-6
King LE, Rodriguez-Enriquez R, Pedley R, Mellor CEL, Wang P, Zindy E, White MRH, Brennan K, Gilmore AP. Apoptotic priming is defined by the dynamic exchange of Bcl-2 proteins between mitochondria and cytosol. Cell Death Differ. 2022;29(11):2262–74.
pubmed: 35585181
pmcid: 9613888
doi: 10.1038/s41418-022-01013-z
Guo YE, Liu Y, Zhang W, Luo H, Shu P, Chen G, Li Y. The clinicopathological characteristics, prognosis and immune microenvironment mapping in MSI-H/MMR-D endometrial carcinomas. Discov Oncol. 2022;13(1):12.
pubmed: 35239036
pmcid: 8894509
doi: 10.1007/s12672-022-00466-5
Zhang J, Zhang G, Zhang W, Bai L, Wang L, Li T, Yan L, Xu Y, Chen D, Gao W, Gao C, Chen C, Ren M, Jiao Y, Qin H, Sun Y, Zhi L, Qi Y, Zhao J, Liu Q, Liu H, Wang Y. Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer. Cell Death Differ. 2022;29(11):2247–61.
pubmed: 35538152
pmcid: 9613699
doi: 10.1038/s41418-022-01012-0
Wang Y, Zheng L, Shang W, Yang Z, Li T, Liu F, Shao W, Lv L, Chai L, Qu L, Xu Q, Du J, Liang X, Zeng J, Jia J. Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer. Cell Death Differ. 2022;29(11):2190–202.
pubmed: 35534546
pmcid: 9613693
doi: 10.1038/s41418-022-01008-w
Scimeca M, Urbano N, Bonfiglio R, Schillaci O, Bonanno E. Management of oncological patients in the digital era: anatomic pathology and nuclear medicine teamwork. Future Oncol. 2018;14(11):1013–5.
pubmed: 29623724
doi: 10.2217/fon-2017-0698
Schillaci O, Scimeca M, Toschi N, Bonfiglio R, Urbano N, Bonanno E. Combining diagnostic imaging and pathology for improving diagnosis and prognosis of cancer. Contrast Media Mol Imaging. 2019;2019:9429761.
pubmed: 31354394
pmcid: 6636452
doi: 10.1155/2019/9429761
Scimeca M, Giocondo R, Montanaro M, Granaglia A, Bonfiglio R, Tancredi V, Mauriello A, Urbano N, Schillaci O, Bonanno E. BMP-2 variants in breast epithelial to mesenchymal transition and microcalcifications origin. Cells. 2020;9(6):1381.
pubmed: 32498363
pmcid: 7348762
doi: 10.3390/cells9061381
Riazalhosseini Y, Lathrop M. Precision medicine from the renal cancer genome. Nat Rev Nephrol. 2016;12(11):655–66.
pubmed: 27694978
doi: 10.1038/nrneph.2016.133
Angelucci S, Sacchetta P, Moio P, Melino S, Petruzzelli R, Gervasi P, Di Ilio C. Purification and characterization of glutathione transferases from the sea bass (Dicentrarchus labrax) liver. Arch Biochem Biophys. 2000;373(2):435–41.
pubmed: 10620369
doi: 10.1006/abbi.1999.1569
Koessinger AL, Cloix C, Koessinger D, Heiland DH, Bock FJ, Strathdee K, Kinch K, Martínez-Escardó L, Paul NR, Nixon C, Malviya G, Jackson MR, Campbell KJ, Stevenson K, Davis S, Elmasry Y, Ahmed A, O’Prey J, Ichim G, Schnell O, Stewart W, Blyth K, Ryan KM, Chalmers AJ, Norman JC, Tait SWG. Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics. Cell Death Differ. 2022;29(10):2089–104.
pubmed: 35473984
pmcid: 9525582
doi: 10.1038/s41418-022-01001-3
Favaloro B, Tamburro A, Angelucci S, Luca AD, Melino S, di Ilio C, Rotilio D. Molecular cloning, expression and site-directed mutagenesis of glutathione S-transferase from Ochrobactrum anthropi. Biochem J. 1998;335(Pt 3):573–9.
pubmed: 9794797
pmcid: 1219818
doi: 10.1042/bj3350573
Servadei F, Anemona L, Cardellini M, Scimeca M, Montanaro M, Rovella V, Di Daniele F, Giacobbi E, Legramante IM, Noce A, Bonfiglio R, Borboni P, Di Daniele N, Ippoliti A, Federici M, Mauriello A. The risk of carotid plaque instability in patients with metabolic syndrome is higher in women with hypertriglyceridemia. Cardiovasc Diabetol. 2021;20(1):98.
pubmed: 33957931
pmcid: 8103747
doi: 10.1186/s12933-021-01277-8
Bonfiglio R, Galli F, Varani M, Scimeca M, Borri F, Fazi S, Cicconi R, Mattei M, Campagna G, Schönberger T, Raymond E, Wunder A, Signore A, Bonanno E. Extensive histopathological characterization of inflamed bowel in the dextran sulfate sodium mouse model with emphasis on clinically relevant biomarkers and targets for drug development. Int J Mol Sci. 2021;22(4):2028.
pubmed: 33670766
pmcid: 7923003
doi: 10.3390/ijms22042028
Han Y, Rovella V, Smirnov A, Buonomo OC, Mauriello A, Perretta T, Shi Y, Woodmsith J, Bischof J, Melino G, Candi E, Bernassola F, TOR CENTRE. A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient. Cell Death Discov. 2023;9(1):370.
pubmed: 37813891
pmcid: 10562433
doi: 10.1038/s41420-023-01651-3
Melino S, Leo S, Toska Papajani V. Natural hydrogen sulfide donors from Allium sp. as a nutraceutical approach in type 2 diabetes prevention and therapy. Nutrients. 2019;11(7):1581.
pubmed: 31336965
pmcid: 6682899
doi: 10.3390/nu11071581
Sunzini F, De Stefano S, Chimenti MS, Melino S. Hydrogen Sulfide as Potential Regulatory Gasotransmitter in Arthritic Diseases. Int J Mol Sci. 2020;21(4):1180. doi: https://doi.org/10.3390/ijms21041180 . Erratum in: Int J Mol Sci. 2020;21(17)
Vitali A, Botta B, Delle Monache G, Zappitelli S, Ricciardi P, Melino S, Petruzzelli R, Giardina B. Purification and partial characterization of a peroxidase from plant cell cultures of Cassia didymobotrya and biotransformation studies. Biochem J. 1998;331(Pt 2):513–9.
pubmed: 9531492
pmcid: 1219383
doi: 10.1042/bj3310513
Aceto A, Dragani B, Melino S, Allocati N, Masulli M, Di Ilio C, Petruzzelli R. Identification of an N-capping box that affects the alpha 6-helix propensity in glutathione S-transferase superfamily proteins: a role for an invariant aspartic residue. Biochem J. 1997;322(Pt 1):229–34.
pubmed: 9078266
pmcid: 1218181
doi: 10.1042/bj3220229
Yang X, Smirnov A, Buonomo OC, Mauriello A, Shi Y, Bischof J, Woodsmith J, Melino G, Candi E, Bernassola F, TOR CENTRE. A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency. Cell Death Discov. 2023;9(1):365.
pubmed: 37783677
pmcid: 10545677
doi: 10.1038/s41420-023-01650-4
McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–303.
pubmed: 20644199
pmcid: 2928508
doi: 10.1101/gr.107524.110
van der Auwera G, O’Connor BD. Genomics in the cloud: using docker, GATK, and WDL in terra. O’Reilly Media Incorporated; 2020.
Kim S, Scheffler K, Halpern AL, Bekritsky MA, Noh E, Källberg M, Chen X, Kim Y, Beyter D, Krusche P, Saunders CT. Strelka2: fast and accurate calling of germline and somatic variants. Nat Methods. 2018;15(8):591–4.
pubmed: 30013048
doi: 10.1038/s41592-018-0051-x
Koboldt DC, Chen K, Wylie T, Larson DE, McLellan MD, Mardis ER, Weinstock GM, Wilson RK, Ding L. VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics. 2009;25(17):2283–5.
pubmed: 19542151
pmcid: 2734323
doi: 10.1093/bioinformatics/btp373
Larson DE, Harris CC, Chen K, Koboldt DC, Abbott TE, Dooling DJ, Ley TJ, Mardis ER, Wilson RK, Ding L. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics. 2012;28(3):311–7.
pubmed: 22155872
doi: 10.1093/bioinformatics/btr665
Ha G, Roth A, Khattra J, Ho J, Yap D, Prentice LM, Melnyk N, McPherson A, Bashashati A, Laks E, Biele J, Ding J, Le A, Rosner J, Shumansky K, Marra MA, Gilks CB, Huntsman DG, McAlpine JN, Aparicio S, Shah SP. TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. Genome Res. 2014;24(11):1881–93.
pubmed: 25060187
pmcid: 4216928
doi: 10.1101/gr.180281.114
Rausch T, Zichner T, Schlattl A, Stütz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012;28(18):i333–9.
pubmed: 22962449
pmcid: 3436805
doi: 10.1093/bioinformatics/bts378
Chen X, Schulz-Trieglaff O, Shaw R, Barnes B, Schlesinger F, Källberg M, Cox AJ, Kruglyak S, Saunders CT. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2016;32(8):1220–2.
pubmed: 26647377
doi: 10.1093/bioinformatics/btv710
Manders F, Brandsma AM, de Kanter J, Verheul M, Oka R, van Roosmalen MJ, van der Roest B, van Hoeck A, Cuppen E, van Boxtel R. MutationalPatterns: the one stop shop for the analysis of mutational processes. BMC Genomics. 2022;23(1):134.
pubmed: 35168570
pmcid: 8845394
doi: 10.1186/s12864-022-08357-3
Melino S, Nepravishta R, Bellomaria A, Di Marco S, Paci M. Nucleic acid binding of the RTN1-C C-terminal region: toward the functional role of a reticulon protein. Biochemistry. 2009;48(2):242–53.
pubmed: 19140693
doi: 10.1021/bi801407w
Gallo M, Paludi D, Cicero DO, Chiovitti K, Millo E, Salis A, Damonte G, Corsaro A, Thellung S, Schettini G, Melino S, Florio T, Paci M, Aceto A. Identification of a conserved N-capping box important for the structural autonomy of the prion alpha 3-helix: the disease associated D202N mutation destabilizes the helical conformation. Int J Immunopathol Pharmacol. 2005;18(1):95–112.
pubmed: 15698515
doi: 10.1177/039463200501800111
Huang MN, McPherson JR, Cutcutache I, Teh BT, Tan P, Rozen SG. MSIseq: software for assessing microsatellite instability from catalogs of somatic mutations. Sci Rep. 2015;5:13321.
pubmed: 26306458
doi: 10.1038/srep13321
Oza VH, Fisher JL, Darji R, Lasseigne BN. CINmetrics: an R package for analyzing copy number aberrations as a measure of chromosomal instability. PeerJ. 2023;11: e15244.
pubmed: 37123011
pmcid: 10143595
doi: 10.7717/peerj.15244
Grendár M, Martínek P, Loderer D, Ondič O. CNHplus: the chromosomal copy number heterogeneity which respects biological constraints. bioRxiv. 2022. https://doi.org/10.1101/2022.09.30.510279 .
doi: 10.1101/2022.09.30.510279
Spurr LF, Touat M, Taylor AM, Dubuc AM, Shih J, Meredith DM, Pisano WV, Meyerson ML, Ligon KL, Cherniack AD, Li YY, Beroukhim R. Quantification of aneuploidy in targeted sequencing data using ASCETS. Bioinformatics. 2021;37(16):2461–3.
pubmed: 33247715
doi: 10.1093/bioinformatics/btaa980
Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24–6.
pubmed: 21221095
pmcid: 3346182
doi: 10.1038/nbt.1754